These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24761803)

  • 41. Estrogen and progesterone receptor status in breast cancer: effect of oral contraceptive pills and hormone replacement therapy.
    Tewari M; Pradhan S; Singh U; Shukla HS
    Breast; 2007 Oct; 16(5):540-5. PubMed ID: 17587581
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cumulative menstrual months and breast cancer risk by hormone receptor status and ethnicity: The Breast Cancer Etiology in Minorities Study.
    Cole SE; John EM; Hines LM; Phipps AI; Koo J; Ingles SA; Baumgartner KB; Slattery ML; McKean-Cowden R; Wu AH
    Int J Cancer; 2022 Jan; 150(2):208-220. PubMed ID: 34469597
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
    Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
    JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of age, tumor size, lymph node metastasis, stage, receptor status and menopausal status on overall survival of breast cancer patients in Pakistan.
    Mahmood H; Faheem M; Mahmood S; Sadiq M; Irfan J
    Asian Pac J Cancer Prev; 2015; 16(3):1019-24. PubMed ID: 25735323
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Breast Cancer Survival Defined by Biological Receptor and Menopausal Status in Vietnamese Women.
    Vu Hong T; Nguyen Ba D; Skoog L; Ta Thanh V; Tani E
    Cancer Control; 2019; 26(1):1073274819865279. PubMed ID: 31343899
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
    Umamaheswaran G; Kadambari D; Muthuvel SK; Kalaivani S; Devi J; Damodaran SE; Pradhan SC; Dubashi B; Dkhar SA; Adithan C
    Breast Cancer Res Treat; 2020 Jul; 182(1):147-158. PubMed ID: 32385792
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
    Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
    Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hormone receptor status in breast cancer--a comparison between surgical specimens and fine needle aspiration biopsies.
    Löfgren L; Skoog L; von Schoultz E; Tani E; Isaksson E; Fernstad R; Carlström K; von Schoultz B
    Cytopathology; 2003 Jun; 14(3):136-42. PubMed ID: 12828723
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The estrogen receptor/progesterone receptor quotient as an index of the transcriptional activity of estrogen receptors in breast cancer].
    Navarro MA; Díez Gibert O; Fernández-Montolí ME; Rosel P; Bonnin MR
    Med Clin (Barc); 1995 May; 104(18):681-2. PubMed ID: 7769876
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study.
    Bardia A; Olson JE; Vachon CM; Lazovich D; Vierkant RA; Wang AH; Limburg PJ; Anderson KE; Cerhan JR
    Breast Cancer Res Treat; 2011 Feb; 126(1):149-55. PubMed ID: 20669045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. One-Year Neoadjuvant Endocrine Therapy in Breast Cancer.
    Rusz O; Vörös A; Varga Z; Kelemen G; Uhercsák G; Nikolényi A; Ormándi K; Simonka Z; Kahán Z
    Pathol Oncol Res; 2015 Sep; 21(4):977-84. PubMed ID: 25753983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies.
    Enger SM; Ross RK; Paganini-Hill A; Carpenter CL; Bernstein L
    Cancer Epidemiol Biomarkers Prev; 2000 Jul; 9(7):681-7. PubMed ID: 10919738
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.
    Yu KD; Di GH; Wu J; Lu JS; Shen KW; Liu GY; Shen ZZ; Shao ZM
    J Cancer Res Clin Oncol; 2008 Dec; 134(12):1347-54. PubMed ID: 18488249
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dietary fiber intake and risk of postmenopausal breast cancer defined by estrogen and progesterone receptor status--a prospective cohort study among Swedish women.
    Suzuki R; Rylander-Rudqvist T; Ye W; Saji S; Adlercreutz H; Wolk A
    Int J Cancer; 2008 Jan; 122(2):403-12. PubMed ID: 17764112
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
    Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis.
    Vrieling A; Buck K; Kaaks R; Chang-Claude J
    Breast Cancer Res Treat; 2010 Oct; 123(3):641-9. PubMed ID: 20711809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
    Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N
    PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.
    Enomoto Y; Morimoto T; Nishimukai A; Higuchi T; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Nomura T; Takeda M; Watanabe T; Hirota S; Miyoshi Y
    Int J Clin Oncol; 2016 Apr; 21(2):254-261. PubMed ID: 26338270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.